Form 4: Tenon Medical CEO Granted 281,872 Restricted Stock Units

Tenon Medical, Inc. CEO and President Steven M. Foster was granted 281,872 restricted stock units, vesting in two tranches in 2026.

Summary

• Steven M. Foster, the CEO and President of Tenon Medical, Inc. (TNON), was granted 281,872 Restricted Stock Units (RSUs).
• The transaction date for this grant was October 13, 2025.
• Each RSU represents a contingent right to receive one share of Tenon Medical's common stock.
• Fifty percent (50%) of the total RSUs, or 140,936 units, are scheduled to vest and convert into common stock on January 1, 2026.
• The remaining fifty percent (50%) of the RSUs, or 140,936 units, are scheduled to vest and convert into common stock on July 31, 2026.
• Following this reported transaction, Steven M. Foster beneficially owns 281,872 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to the CEO is generally a positive signal for corporate governance and management alignment with shareholder interests. It incentivizes long-term performance and retention. However, it does not directly reflect operational or financial performance, hence a moderately positive score.

Positives

• The grant of Restricted Stock Units to the CEO aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This RSU grant serves as a retention incentive for the CEO, encouraging continued leadership and commitment to the company's long-term success.

Future Outlook

The future outlook indicates that Steven M. Foster will acquire 281,872 shares of Tenon Medical common stock upon the vesting of his Restricted Stock Units in two tranches during 2026, contingent on his continued employment and the company's performance.

Industry Context

This RSU grant is a standard practice in executive compensation across various industries, particularly in medical device and biotechnology sectors, aiming to incentivize long-term performance and retain key leadership.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice across publicly traded companies, including those in the medical technology sector like Tenon Medical.
• The vesting schedule, with tranches over a period, is typical for long-term incentive plans, similar to those observed at comparable medical device companies such as NuVasive, Globus Medical, or Stryker, which often use equity awards to align executive interests with shareholder value over multi-year horizons.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CEO's financial interests with long-term shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: May signal stability in leadership, potentially boosting morale and confidence in the company's direction.
• Management: Provides a significant long-term incentive and retention mechanism for the CEO.

Next Steps

• The vesting of 50% of the Restricted Stock Units on January 1, 2026.
• The vesting of the remaining 50% of the Restricted Stock Units on July 31, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) and does not contain information that would significantly alter the fundamental investment thesis for Tenon Medical. While the grant aligns management interests with shareholders, it is not a direct indicator of operational performance or a catalyst for immediate stock price movement. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial news.

Keywords

Tenon Medical, TNON, Steven Foster, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Form 4